Oculis Holding AG (OCS) Non Operating Interest Expenses (2022 - 2026)
Oculis Holding AG's (OCS) quarterly Non Operating Interest Expenses came in at -$220921.8 in Q1 2026, up 19.58% year-on-year from -$184741.0 in Q1 2025, and up 26.73% quarter-over-quarter from -$301531.9 in Q4 2025.
Oculis Holding AG (OCS) Non Operating Interest Expenses (2022 - 2026) Analysis & Trends
Oculis Holding AG's Non Operating Interest Expenses history runs 5 years deep, the most recent figure standing at -$220921.8 for Q1 2026.
- On a quarterly basis, Non Operating Interest Expenses rose 19.58% year-over-year to -$220921.8 in Q1 2026; TTM through Mar 2026 was -$203.3 million, a 33.44% increase from a year earlier, with the FY2025 full-year figure at -$1.0 million, down 38.32% from the prior year.
- Non Operating Interest Expenses climbed to -$220921.8 in Q1 2026 per OCS's latest filing, from -$301531.9 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at -$12453.7 in Q3 2023 and bottomed at -$304.7 million in Q3 2024.
- The 5-year median for Non Operating Interest Expenses is -$278340.9 (2025), against an average of -$32.2 million.
- Across the five-year window, Non Operating Interest Expenses jumped 99.34% in 2023 and plunged 2446652.74% in 2024, its largest moves.
- Year by year, Non Operating Interest Expenses stood at -$1.4 million in 2022, then surged by 99.01% to -$13528.3 in 2023, then slumped by 1984.2% to -$281955.9 in 2024, then declined by 6.94% to -$301531.9 in 2025, then increased by 26.73% to -$220921.8 in 2026.
- Per Business Quant, the three latest OCS Non Operating Interest Expenses figures stand at -$220921.8 (Q1 2026), -$301531.9 (Q4 2025), and -$202.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -220,921.81 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -220,921.81 |
| Dec 31, 2025 | -301,531.92 |
| Sep 30, 2025 | -202.52 Mn |
| Jun 30, 2025 | -221,043.91 |
| Mar 31, 2025 | -274,725.88 |
| Dec 31, 2024 | -281,955.90 |
| Sep 30, 2024 | -304.71 Mn |
| Jun 30, 2024 | -96,204.03 |
| Mar 31, 2024 | -46,972.97 |
| Dec 31, 2023 | -13,528.25 |
| Sep 30, 2023 | -12,453.68 |
| Jun 30, 2023 | -18,906.98 |
| Mar 31, 2023 | -1.38 Mn |
| Dec 31, 2022 | -1.37 Mn |
| Sep 30, 2022 | -1.90 Mn |
| Jun 30, 2022 | -1.73 Mn |